A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension

Indian Journal of Pharmacology

Volumn 48, Issue 5, 2016, Pages 503-508

  Chogtu, Bharti ^a   Kuriachan, Sanitha ^a   Magazine, Rahul ^a   Shetty, K ^a   Kamath, Asha ^a   George, Manu ^a   Tripathy, Amruta ^a   Kumar, D ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Borg's dyspnea score; chronic obstructive pulmonary disease; echocardiogram; hyperlipidemia; pulmonary function tests; quality of life

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; PLACEBO; ROSUVASTATIN; ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EXERCISE; FOOT EDEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MIDDLE AGED; MYALGIA; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH DISEASE; TREATMENT DURATION; DRUG EFFECTS; FEMALE; HYPERTENSION, PULMONARY; MALE; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VITAL CAPACITY; WALKING;

AGED; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; VITAL CAPACITY; WALKING;

EID: 84988579196     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.190721     Document Type: Article

References (30)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis and Management and Prevention of COPD. Available from: http://www. goldcopd. org. [Last updated on 2014 Jan 30].
2. Magee F, Wright JL, Wiggs BR, Paré PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988;43:183-9.
3. Wright JL, Lawson L, Paré PD, Hooper RO, Peretz DI, Nelems JM, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis 1983;128:702-7.
4. Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010;74:818-26.
5. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010;65:930-6.
6. Duong-Quy S, Dao P, Hua-Huy T, Guilluy C, Pacaud P, Dinh-Xuan AT. Increased Rho-kinase expression and activity and pulmonary endothelial dysfunction in smokers with normal lung function. Eur Respir J 2011;37:349-55.
7. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
8. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-9.
9. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
10. Global Initiative for Chronic Obstructive Lung Disease. Spirometry for Health Care Providers; 2010. Available from: http://www. goldcopd. org/uploads/users/files/GOLD-Spirometry-2010. pdf. [Last cited on 2014 Oct 13].
11. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.
12. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler 2003;4:9-14.
13. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: Additional results from the STELLAR trial. Clin Ther 2004;26:1388-99.
14. Meister KE. Rosuvastatin: A New Pharmacotherapy for LDL-Cholesterol Reduction. Pharmacotherapy Update; 2003. Available from: http://www. clevelandclinicmeded. com/ medicalpubs/pharmacy/novdec2003/rosuvastatin. htm. [Last cited on 2014 Oct 26].
15. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax 2004;59:574-80.
16. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 2015;70:33-40.
17. Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370:2201-10.
18. Neukamm A, Hoiseth A, Einvik G, Hagve TA, Lehmann S, Soyseth V, et al. Effect of Rosuvastatin in stable COPD (RODEO)-A randomized double blind clinical trial. Am J Respir Crit Care Med 2014;189:A6564.
19. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-71.
20. Chan-Yeung M, Carlsten C. Reasonable alternatives to spirometry for diagnosing chronic obstructive pulmonary disease: Is the peak flow meter the answer? Int J Tuberc Lung Dis 2009;13:279-80.
21. Si XB, Zhang S, Huo LY, Dai WL, Wang HL. Statin therapy does not improve lung function in asthma: A meta-analysis of randomized controlled trials. J Int Med Res 2013;41:276-83.
22. Zeng WJ, Xiong CM, Zhao L, Shan GL, Liu ZH, Xue F, et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J 2012;40:67-74.
23. Rubinstein J, Aloka F, Abela GS. Statin therapy decreases myocardial function as evaluated via strain imaging. Clin Cardiol 2009;32:684-9.
24. Qie L, Meng X, Wang Y, Feng M, Zhong M, Li L. Assessment of regional systolic and diastolic functions affected by atorvastatin in coronary artery disease using tissue Doppler imaging. Clin Cardiol 2008;31:551-5.
25. Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 2008;72:538-44.
26. Correale M, Brunetti ND, Totaro A, Montrone D, Russo AR, Fanigliulo AM, et al. Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: Results from the Daunia Heart Failure Registry. Clinics (Sao Paulo) 2011;66:777-84.
27. Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010;104:1877-82.
28. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009;136:412-9.
29. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: Evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373-8.
30. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158-64.